Comparatively, although HER2/neu-low-expressing or triple-negative patients are “negative” for HER2/neu expression but expressed at the non-detectable or negligible level, increasing the exposure to HER2/neu epitope via vaccination with li-Key hybrid can promote the immune recognition of these cancer cells as long as they express some but a few HER2/neu proteins. The gene discussed is ERBB2; the disease is cancer.